LUPIN vs ZYDUSLIFE: Stock Comparison

Lupin Limited vs Zydus Lifesciences Ltd

Live data: 22 July 2026, 2:41 PM IST • Source: NSE and company filings

Zydus Lifesciences Ltd is the larger company by market capitalisation. Lupin Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Zydus Lifesciences Ltd shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lupin Limited and Zydus Lifesciences Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LUPIN is more favourable on 11 of 13 scored metrics and ZYDUSLIFE on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
ZYDUSLIFE is the larger company
₹1.12 L Cr vs ₹1.1 L Cr
P/E Ratio
LUPIN has a lower P/E
21.56x vs 22.82x
P/B Ratio
ZYDUSLIFE has a lower P/B
4.24x vs 5.12x
EPS
LUPIN has higher earnings per share
₹116.56 vs ₹50.1
Dividend Yield
LUPIN has a higher dividend yield
0.48% vs 0.09%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 16.2%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs 8.7%
Qtr Sales Growth
LUPIN has stronger quarterly sales growth
31.9% vs 16.2%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLUPINZYDUSLIFE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLUPINZYDUSLIFE
Live Price₹2,413.4₹1,119.9
Day Change-4.03%-2.03%
Volume9.76 L12.87 L
52-Week High₹2,529.5₹1,181.5
52-Week Low₹1,836.8₹835.5
Distance from 52W High-4.59%-5.21%

Valuation

MetricLUPINZYDUSLIFE
Market Cap₹1.1 L Cr₹1.12 L Cr
P/E Ratio21.56x22.82x
P/B Ratio5.12x4.24x
EPS₹116.56₹50.1
Book Value₹491.29₹269
Dividend Yield0.48%0.09%

Growth

MetricLUPINZYDUSLIFE
Revenue Growth (TTM YoY)31.9%16.2%
EPS Growth (TTM YoY)89%8.7%
Qtr Sales Growth31.9%16.2%
Qtr Profit Growth101%21.9%

Profitability & Leverage

MetricLUPINZYDUSLIFE
ROE29.1%21.2%
ROCE30.3%21.1%
Net Margin17.65%18.36%
Operating Margin31.5%31.2%
Debt to Equity0.29x0.46x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLUPINZYDUSLIFE
Promoter Holding46.57% 0.04 pp75.01% 0.01 pp
FII Holding21.71% 0.22 pp6.88% 0.07 pp
DII Holding25.32% 0.26 pp11.27% 0.07 pp
Public Holding6.11% 0.08 pp6.83% 0.03 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lupin Limited and Zydus Lifesciences Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.